Relay Therapeutics (RLAY)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Precision Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 6.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 34.37% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value
- Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?
- X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
- Relay Therapeutics CFO Sells 17,717 Shares for $350,000
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
- This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
- Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
- Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- A novel technique of magnetically guided single-pass limbal extraction for intraocular foreign bodies: Eliminating the need for intraocular instrument relay. — Graefes Arch Clin Exp Ophthalmol 2026 Sep 11 PMID 42726115
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Relay Therapeutics.
Full RLAY Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.